ImmuneOncia Therapeutics
ImmuneOncia Therapeutics is a South Korea-based biotechnology company running 2 late-stage cancer trials of IMC-001 in peripheral T-cell lymphomas.
Overview
ImmuneOncia Therapeutics, based in Yongin-si, South Korea, is a biotechnology company. ImmuneOncia Therapeutics develops immuno-oncology antibody drugs, stating its aim is to bring Korea's first immuno-oncology drug to market. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing IMC-001 in peripheral T-cell lymphomas. The largest, NCT06365840 (A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumour), plans to enrol 30 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry, checked on 2026-09-11; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyHaihe Biopharma
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag ctgov-sponsor.
- CompanyBioInvent International
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag ctgov-sponsor.
- CompanyEvopoint Biosciences
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag ctgov-sponsor.